Arcus Ventures

Arcus Ventures is a venture capital firm based in New York, specializing in investments in oncology-focused companies. Established in 2007, the firm targets early-stage companies that are developing innovative biopharmaceuticals, new drug delivery platforms, and medical devices with pre-marketing approval. Additionally, Arcus Ventures invests in service companies generating positive revenue, emphasizing the importance of proprietary technology and design in its portfolio. The firm was founded by Steven L. Soignet and James B. Dougherty, and it is committed to advancing cancer treatment through its strategic investments.

James Dougherty

Co-Founder & General Partner

Chad C. Hellmann

CFO

Myoung-Ok Kwon Ph.D

Venture Partner

Sandra Panem Ph.D

Advisor

Steven Soignet

Co-Founder & General Partner

24 past transactions

Oncoscope

Venture Round in 2010
Oncoscope, Inc. operates as a medical device company. It develops optical imaging systems for epithelial tissues in the oral cavity, esophagous, stomach, colon, lung, cervix, and bladder. Its systems provide in vivo measurements of the diameter and density of cell nuclei. The company was founded in 2006 and is based in Durham, North Carolina.

Cleave Therapeutics

Private Placement in 2019
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

T2 Biosystems

Series D in 2011
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

TRACON Pharmaceuticals

Series A in 2011
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC093, a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding cleaved collagen in the extracellular matrix of solid tumors; TRC105, a human chimeric monoclonal antibody that binds endoglin for angiogenesis; TRC102, a molecule that reverses resistance to chemotherapeutics; and TRC101, a nanoliposome embedded with ceramide used to improve the activity and delivery of chemotherapeutics. TRACON Pharmaceuticals, Inc. was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in April 2005. The company was founded in 2005 and is based in San Diego, California.

Palyon Medical

Seed Round in 2008
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

Cleave Therapeutics

Series C in 2019
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

MacroGenics

Series D in 2008
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

MI Bioresearch

Series B in 2013
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

Exosome Diagnostics

Series B in 2016
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics

Series B in 2015
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

XTuit Pharmaceuticals

Series A in 2015
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.

MI Bioresearch

Series A in 2011
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

MI Bioresearch

Series A in 2012
MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

Epic Sciences

Series C in 2014
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Oncoscope

Seed Round in 2011
Oncoscope, Inc. operates as a medical device company. It develops optical imaging systems for epithelial tissues in the oral cavity, esophagous, stomach, colon, lung, cervix, and bladder. Its systems provide in vivo measurements of the diameter and density of cell nuclei. The company was founded in 2006 and is based in Durham, North Carolina.

Cleave Therapeutics

Series B in 2016
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

TRACON Pharmaceuticals

Private Placement in 2018
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, develops, licenses, and commercializes targeted therapies for cancer and age-related macular degeneration. Its products include TRC093, a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth, and cancer metastasis by binding cleaved collagen in the extracellular matrix of solid tumors; TRC105, a human chimeric monoclonal antibody that binds endoglin for angiogenesis; TRC102, a molecule that reverses resistance to chemotherapeutics; and TRC101, a nanoliposome embedded with ceramide used to improve the activity and delivery of chemotherapeutics. TRACON Pharmaceuticals, Inc. was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in April 2005. The company was founded in 2005 and is based in San Diego, California.

Exosome Diagnostics

Series C in 2017
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics

Series B in 2014
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

T2 Biosystems

Series E in 2013
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

T2 Biosystems

Series C in 2010
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Vascular Pathways

Series B in 2010
Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion.